Chest
Asthma: Original ResearchReal-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
Section snippets
Study Design and Approval
We performed a retrospective analysis of all patients with SEA who commenced treatment with benralizumab between May 2018 and April 2019 at our tertiary referral asthma center in the United Kingdom. Ethical approval was gained from the LondonāBloomsbury Research Ethics Committee (Identifier: 15/LO/0886).
Study Participants
All patients were reviewed by an asthma physician, fulfilled the ERS/ATS definition of severe asthma,15 and had confirmed adherence to background therapy (via ICS or long-acting Ī²2 agonist
Results
A total of 136 patients began benralizumab therapy, with 6 patients excluded from the analysis because they stopped treatment before 24Ā weeks: 3 did not complete clinic follow-up; 2 stopped because of presumed medication-related adverse events; and 1 stopped because of pregnancy. A further 7 patients stopped between 24 and 48Ā weeks because of suboptimal response; these patients were included in the analysis. The baseline characteristics of the included patients (nĀ = 130) reflected those of
Discussion
We report real-world experience of using the anti-IL5-receptor monoclonal antibody benralizumab in a large cohort of patients with SEA. We observed that benralizumab leads to clinically and statistically significant reductions in asthma exacerbations, with more than 40%Ā of patients remaining exacerbation-free at 1 year. This was achieved despite a median reduction in mOCS dose of 100%, with 70%Ā of patients able to stop mOCS therapy for asthma. Marked improvements in the patient-reported outcome
Acknowledgments
Author contributions: J. E. K. takes responsibility for the integrity of the data and analysis. G. dāA., C. R., M. F., L. G., and L. T. contributed to data collection. J. E. F., A. P. H., A. D., J. D., A. M. N., B. D. K., and D. J. J. contributed to the study design, data analysis and interpretation, and the writing of the manuscript.
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: D. J., B. K., and G. d'A. report advisory board and speaker fees and congress
References (21)
- et al.
The prevalence of severe refractory asthma
JĀ Allergy Clin Immunol
(2015) - et al.
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
JĀ Allergy Clin Immunol
(2001) - et al.
Real-world effectiveness and the characteristics of a āsuper-responderā to mepolizumab in severe eosinophilic asthma
Chest
(2020) - et al.
Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab
Drug Saf
(2020) - et al.
Benralizumab, an anti-interleukin-5 receptor Ī± monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet
(2016) - et al.
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Lancet
(2016) - et al.
Characterization of severe asthma worldwide: data from the International Severe Asthma Registry
Chest
(2020) - et al.
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Lancet Respir Med
(2017) Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions
Curr Opin Mol Ther
(2009)- et al.
Dupilumab in persistent asthma with elevated eosinophil levels
NĀ Engl J Med
(2013)
Cited by (0)
FUNDING/SUPPORT: The authors have reported to CHEST that no funding was received for this study.